Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Long-Term Debt Repayments (2018 - 2025)

Historic Long-Term Debt Repayments for Guided Therapeutics (GTHP) over the last 8 years, with Q3 2025 value amounting to $94000.0.

  • Guided Therapeutics' Long-Term Debt Repayments rose 7407.41% to $94000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $511000.0, marking a year-over-year increase of 7992.96%. This contributed to the annual value of $438000.0 for FY2024, which is 631.07% up from last year.
  • Latest data reveals that Guided Therapeutics reported Long-Term Debt Repayments of $94000.0 as of Q3 2025, which was up 7407.41% from $71000.0 recorded in Q2 2025.
  • Over the past 5 years, Guided Therapeutics' Long-Term Debt Repayments peaked at $811000.0 during Q2 2021, and registered a low of $41000.0 during Q2 2023.
  • For the 5-year period, Guided Therapeutics' Long-Term Debt Repayments averaged around $180588.2, with its median value being $94000.0 (2025).
  • As far as peak fluctuations go, Guided Therapeutics' Long-Term Debt Repayments tumbled by 9469.79% in 2022, and later soared by 34222.22% in 2024.
  • Guided Therapeutics' Long-Term Debt Repayments (Quarter) stood at $811000.0 in 2021, then plummeted by 90.75% to $75000.0 in 2022, then plummeted by 40.0% to $45000.0 in 2023, then surged by 342.22% to $199000.0 in 2024, then plummeted by 52.76% to $94000.0 in 2025.
  • Its Long-Term Debt Repayments stands at $94000.0 for Q3 2025, versus $71000.0 for Q2 2025 and $147000.0 for Q1 2025.